CD19 Positive clinical trials at UC Health
1 research study open to eligible people
“Study of Immunotherapy (Lenalidomide and Blinatumomab) looking at side effects and best dose for treatment of lymphoma”
open to eligible people ages 18 years and up
This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement. Biological therapies, such as lenalidomide and blinatumomab, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing.
at UCSD UC Davis